Boston Scientific launches Synergy stent trial
Boston Scientific says it's enrolled the 1st patient in the Evolve II clinical trial of its Synergy drug-eluting stent, in support of regulatory approvals in the U.S. and Japan.
Boston Scientific (NYSE:BSX) said the 1st patient was enrolled in the Evolve II clinical trial of its Synergy drug-eluting stent, aiming to use the data to back applications for approval in the U.S. and Japan.
The Natick, Mass.-based medical device company's everolimus-coated stent uses a bioabsorbable polymer designed to elute the drug for 3 months, leaving a bare platinum-chromium stent behind.
The 2,000-patient trial will follow its subjects for 5 years, according to a press release.